AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Quality of Life-Guided Transfusion in Refractory MDS or AML

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire de Nice
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of clinical benefit in this setting. This prospective randomized study compares a standard hemoglobin-based transfusion strategy to a quality-of-life-guided strategy using the EQ-5D-5L questionnaire, with the aim of reducing transfusion burden while maintaining patient safety and quality of life.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years and older. * Diagnosis of refractory MDS or AML, receiving palliative care only. * Anaemia with haemoglobin โ‰ค 8 g/dl at inclusion (or โ‰ค 9 g/dl if associated with cardiovascular disease). * Transfusion dependency, defined as requiring more than 2 GR transfusions every 8 weeks. * No vitamin B9, vitamin B12 or iron deficiency. * Ability to understand and sign the informed consent form. * Ability to comply with the schedule of visits and other protocol requirements. Non inclusion Criteria: * Previous malignant disease other than MDS or AML (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast). * Active uncontrolled infection (hepatitis B or C, HIV). * Use of G-CSF. * Confirmed neurocognitive disorders (based on prior diagnosis or clinical assessment by the investigator) impairing comprehension, consent or the ability to reliably complete the EQ-5D-5L questionnaire. * Active uncontrolled heart disease. * Active haemolytic anaemia. * Recent major surgery. * Life-threatening complications of MDS/AML. * Presence of another serious or unstable disease which, in the investigators' opinion, would make participation in the study inappropriate or risky for the patient's safety. * Vulnerable individuals. Exclusion Criteria: * Immediate severe complications related to MDS/AML, such as uncontrolled bleeding, pneumonia with hypoxia or shock, or severe disseminated intravascular coagulopathy. * Withdrawal of the patient's voluntary informed consent.
๐Ÿ’Š

What it tests

  • Red blood cell transfusions based on EQ-5D-5L questionnaire
๐Ÿ“

Where

1 site
CHU de Nice
Nice, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy